Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05297812

Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease

Sponsor: Columbia University

View on ClinicalTrials.gov

Summary

Alpha-1 Anti-trypsin Deficiency (AATD) is a genetic disease with lung and liver disease presentations. The purpose of this study is to examine the density of the lung as measured by chest computed tomography (CT) and determine if existing emphysema predicts changes in the rate of subsequent emphysema or changes in CT, serum or plasma biomarkers of interest. The overarching goal is to develop biomarkers that can be used in interventional trials since lung function changes do not typically inform disease progression in AATD.

Official title: Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease - Alpha-1 Biomarker Research Consortium (A1BC)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

286

Start Date

2022-03-23

Completion Date

2027-01

Last Updated

2026-01-16

Healthy Volunteers

No

Locations (9)

University of Alabama at Birmingham

Birmingham, Alabama, United States

University of California - Los Angeles

Los Angeles, California, United States

National Jewish Health

Denver, Colorado, United States

University of Chicago

Chicago, Illinois, United States

Boston University

Boston, Massachusetts, United States

Columbia University

New York, New York, United States

University of North Carolina

Chapel Hill, North Carolina, United States

Medical University of South Carolina

Charleston, South Carolina, United States

University of Utah

Salt Lake City, Utah, United States